Straits Times Index
3,273.48 +10.72 (+0.33%) S&P 500
4,283.74 +9.70 (+0.23%) Dow
33,999.04 +18.72 (+0.06%) Nasdaq
12,965.34 +27.22 (+0.21%) BTC-USD
23,370.62 +3.91 (+0.02%) CMC Crypto 200
558.74 +1.01 (+0.18%)
Coherus BioSciences, Inc. (CHRS)
After hours:
| Previous close | 13.08 |
| Open | 13.08 |
| Bid | 12.71 x 1300 |
| Ask | 12.96 x 1400 |
| Day's range | 12.60 - 13.14 |
| 52-week range | 5.60 - 19.32 |
| Volume | |
| Avg. volume | 1,105,020 |
| Market cap | 1.01B |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript
This release can be found on the Coherus BioSciences website and is also attached to our Form 8-K. Today's call includes forward-looking statements regarding Coherus' current expectations about future events. All these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from results, performance or achievements implied by the forward-looking statements.
- Zacks
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Wall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know
The consensus price target hints at an 84.6% upside potential for Coherus BioSciences (CHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
